Evidence map›Paper›PMID 41381514›Full record

ArticleNature communications2025

Mechanistic insights into single-stranded DNA degradation by lysosomal exonucleases PLD3 and PLD4 from structural snapshots.

Yoshinori Hirano, Wakiko Ezaki, Ryota Sato, Umeharu Ohto, Kensuke Miyake, Toshiyuki Shimizu

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yoshinori HiranoGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-9888-1616
Wakiko EzakiGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
Ryota SatoDivision of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Umeharu OhtoGraduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.
Kensuke MiyakeDivision of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Toshiyuki ShimizuGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan. shimizu@mol.f.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-0547-8922

Funding

MEXT | JST | Core Research for Evolutional Science and Technology (CREST) JPMJCR21E4
6 · The paper itself

Abstract

Lysosomal exonuclease phospholipase D (PLD) family PLD3 and PLD4 degrade single-stranded RNA or DNA and regulate TLR7 or TLR9 responses. Polymorphisms of these enzymes are associated with human diseases: PLD4 is associated with inflammatory diseases, and PLD3 is associated with neurodegenerative diseases. Here, we determine the structures of substrate-bound PLD3 and PLD4 by cryo-electron microscopy. Our structures reveal that PLD3 rebuilds a substrate-binding pocket, depending on the substrate, mainly via motion of the Phe335-containing loop. Furthermore, we captured the structure in a metastable state that appears during substrate rearrangement following product release. Together, our findings identify the residues that underlie the distinct activities of PLD3 and PLD4. This study provides a mechanistic basis for the exonuclease activity of PLD3 and PLD4 in single-stranded DNA degradation.

Indexed as

DNA, Single-StrandedLysosomesPhospholipase DBinding SitesCryoelectron MicroscopyExonucleasesHumansModels, MolecularDNA, Single-StrandedExonucleasesPhospholipase D

Identifiers

PMID41381514
PMCPMC12749308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.